Cutler Group’s Verrica Pharmaceuticals VRCA Stock Holding History

Cutler Group’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-220	Closed	-$4K	–	3738
2023 Q4	$4K	Buy	+220	New	+$9.04K	﹤0.01%	2890
2021 Q4	–	Sell	-130	Closed	-$1K	–	6153
2021 Q3	$1K	Buy	+130	New	+$14.6K	﹤0.01%	5472

Other funds holding VRCA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Cutler Group's VRCA Position: Q1 2024 in Review

Cutler Group sold out of Verrica Pharmaceuticals (VRCA) in Q1 2024, closing a stake of 10 shares.

Cutler Group first reported a position in VRCA in Q3 2021 and held it in 2 quarters. The position peaked at $3K in Q3 2021. 60 funds tracked by Wall St. Rank hold VRCA as of Q1 2024.

Cutler Group reported no remaining Verrica Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 10 Verrica Pharmaceuticals shares in Q1 2024.
Cutler Group first reported a position in Verrica Pharmaceuticals in Q3 2021 and held it in 2 quarters.
Cutler Group's Verrica Pharmaceuticals position peaked at $3K in Q3 2021.
60 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.